{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:27:57Z","timestamp":1780478877200,"version":"3.54.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009820","name":"Assistance publique-H\u00f4pitaux de Paris","doi-asserted-by":"publisher","award":["RGPD\/APHM 2019-73"],"award-info":[{"award-number":["RGPD\/APHM 2019-73"]}],"id":[{"id":"10.13039\/501100009820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009820","name":"Assistance publique-H\u00f4pitaux de Paris","doi-asserted-by":"publisher","award":["2019-001"],"award-info":[{"award-number":["2019-001"]}],"id":[{"id":"10.13039\/501100009820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["10-IAHU-03"],"award-info":[{"award-number":["10-IAHU-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010076","name":"Conseil R\u00e9gional Provence-Alpes-C\u00f4te d&apos;Azur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clinre.2022.102035","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:41:52Z","timestamp":1666269712000},"page":"102035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up"],"prefix":"10.1016","volume":"46","author":[{"given":"Clara","family":"Dassetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Borentain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"G\u00e9rolami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-0308","authenticated-orcid":false,"given":"Philippe","family":"Colson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.102035_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106562","article-title":"Hepatitis delta treatment with bulevirtide in real life: a case report","volume":"59","author":"Giordan","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinre.2022.102035_bib0002","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of a \"real world\" study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2022.102035_bib0003","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2022.102035_bib0004","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijantimicag.2019.09.012","article-title":"Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection","volume":"54","author":"Brancaccio","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinre.2022.102035_bib0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/pathogens11050517","article-title":"Efficacy and safety of bulevirtide plus tenofovir disoproxil fumarate in real-world patients with chronic hepatitis B and D co-infection","volume":"11","author":"Herta","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.clinre.2022.102035_bib0006","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in with PEG-interferon alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J Hepatol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:59:50Z","timestamp":1778828390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122001681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":6,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2210740122001681"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102035","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102035"}}